Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery

Bibliography

• Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011;27(1):441-64
   PubMed Web of Science ®Google Scholar
• Yeluri S, Madhok B, Prasad KR, et al. Cancer's craving for sugar: an opportunity for clinical exploitation. J Cancer Res Clin Oncol 2009;135(7):867-77; English
   PubMed Web of Science ®Google Scholar
• Pasteur L. Experiments and novel views on the nature of fermentation. Comp Rend Acad Sci 1861;89:1260-4
   Google Scholar
• Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8(12):967-75
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 2007;39(7–8):1358-66
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Gawlinski ET, Gmitro AF, et al. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006;66(10):5216-23
   PubMed Web of Science ®Google Scholar
• Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, et al. Evidence for a stromal-epithelial “lactate shuttle” in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011;10(11):1772-83
   PubMed Web of Science ®Google Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11(6):393-410
   PubMed Web of Science ®Google Scholar
• Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J 2012;31(11):2448-60
   PubMed Web of Science ®Google Scholar
• Heddleston JM, Li Z, Lathia JD, et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010;102(5):789-95
   PubMed Web of Science ®Google Scholar
• Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414(6863):550-4
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292(5516):468-72
   PubMed Web of Science ®Google Scholar
• Nagy MA. HIF-1 is the commander of gateways to cancer. J Cancer Sci Ther 2011;3(2):35-40
   Google Scholar
• Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3(3):177-85
   PubMed Web of Science ®Google Scholar
• Sasabe E, Tatemoto Y, Li D, et al. Mechanism of HIF-1alpha -dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 2005;96(7):394-402
   PubMed Web of Science ®Google Scholar
• Hellwig-Burgel T, Rutkowski K, Metzen E, et al. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999;94(5):1561-7
   PubMed Web of Science ®Google Scholar
• Richard DE, Berra E, Gothie E, et al. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999;274(46):32631-7
   PubMed Web of Science ®Google Scholar
• Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997;57(23):5328-35
   PubMed Web of Science ®Google Scholar
• Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14(1):34-44
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399(6733):271-5
   PubMed Web of Science ®Google Scholar
• Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14(4):391-6
   PubMed Web of Science ®Google Scholar
• Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008;15(4):678-85
   PubMed Web of Science ®Google Scholar
• Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004;3(5):647-54
   PubMed Web of Science ®Google Scholar
• Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 2012;4(4):376-89
   PubMed Web of Science ®Google Scholar
• Ryder M, Ghossein RA, Ricarte-Filho JC, et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Related Cancer 2008;15(4):1069-74
   PubMed Web of Science ®Google Scholar
• Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2011;2(12):1117-33
   PubMedGoogle Scholar
• Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009;13(9A):2780-6
   PubMed Web of Science ®Google Scholar
• Calvo M, Figueroa A, Pulido E, et al. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol 2010;2010;205357
   PubMedGoogle Scholar
• Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202(3):654-62
   PubMed Web of Science ®Google Scholar
• Krzeslak A, Wojcik-Krowiranda K, Forma E, et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res 2012;18(3):721-8; English
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Saito A, Miyagi Y, et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett 2000;154(2):175-82
   PubMed Web of Science ®Google Scholar
• Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 2003;206(12):2049-57
   PubMed Web of Science ®Google Scholar
• Peng SY, Lai PL, Pan HW, et al. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 2008;19(4):1045-53
   PubMed Web of Science ®Google Scholar
• Palmieri D, Fitzgerald D, Shreeve SM, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 2009;7(9):1438-45
   PubMed Web of Science ®Google Scholar
• Gottlob K, Majewski N, Kennedy S, et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001;15(11):1406-18
   PubMed Web of Science ®Google Scholar
• Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits bax-induced cytochrome c release and apoptosis. J Biol Chem 2002;277(9):7610-18
   PubMed Web of Science ®Google Scholar
• Vora S, Halper JP, Knowles DM. Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation- and progression-linked discriminants of malignancy. Cancer Res 1985;45(7):2993-3001
   PubMed Web of Science ®Google Scholar
• Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452(7184):230-3
   PubMed Web of Science ®Google Scholar
• Telang S, Yalcin A, Clem AL, et al. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 2006;25(55):7225-34
   PubMed Web of Science ®Google Scholar
• Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011;43(7):969-80
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Locasale JW, Swanson KD, et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010;329(5998):1492-9
   PubMed Web of Science ®Google Scholar
• Yamada K, Noguchi T. Regulation of pyruvate kinase M gene expression. Biochem Biophys Res Commun 1999;256(2):257-62
   PubMed Web of Science ®Google Scholar
• Luo W, Hu H, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011;145(5):732-44
   PubMed Web of Science ®Google Scholar
• Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011;108(10):4129-34
   PubMed Web of Science ®Google Scholar
• Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008;8(1):51-6
   PubMed Web of Science ®Google Scholar
• Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. DMM Dis Models Mech 2011;4(6):727-32
   PubMed Web of Science ®Google Scholar
• Semenza GL, Jiang B-H, Leung SW, et al. Hypoxia response elements in the aldolase a, enolase 1, and lactate dehydrogenase a gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996;271(51):32529-37
   PubMed Web of Science ®Google Scholar
• Tas F, Aykan F, Alici S, et al. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 2001;24(6):547-50
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 2012;30(27):3402-7
   PubMed Web of Science ®Google Scholar
• Jin Y, Ye X, Shao L, et al. Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy. Eur J Cancer 2013;49(7):1619-26
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003;89(5):877-85
   PubMed Web of Science ®Google Scholar
• Papandreou I, Cairns RA, Fontana L, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006;3(3):187-97
   PubMed Web of Science ®Google Scholar
• Wigfield SM, Winter SC, Giatromanolaki A, et al. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer 2008;98(12):1975-84
   PubMed Web of Science ®Google Scholar
• Kroemer GP, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' Heel. Cancer Cell 2008;13(6):472-82
   PubMed Web of Science ®Google Scholar
• Sokoloff B, Eddy WH, Saelhof CC, Beach J. Glucose antagonists in experimental cancer. AMA Archiv Pathol 1955;59(6):729-32
   PubMedGoogle Scholar
• Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 2009;61(14):1250-75
   PubMed Web of Science ®Google Scholar
• Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 2009;18(1):77-87
   PubMed Web of Science ®Google Scholar
• Di Cosimo S, Ferretti G, Papaldo P, et al. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barcelona Spain) 1998;39(3):157-74
   Google Scholar
• Welsh S, Williams R, Kirkpatrick L, et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004;3(3):233-44
   PubMed Web of Science ®Google Scholar
• Ellinghaus P, Heisler I, Unterschemmann K, et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med 2013;2(5):611-24
   PubMed Web of Science ®Google Scholar
• Jeong W, Rapisarda A, Park SR, et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1alpha), in patients with refractory solid tumors. Cancer Chemother Pharmacol 2014;73(2):343-8
   PubMed Web of Science ®Google Scholar
• Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 2007;7(7):919-43
   PubMed Web of Science ®Google Scholar
• Liu XQ, Xiong MH, Shu XT, et al. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Mol Pharm 2012;9(10):2863-74
   PubMedGoogle Scholar
• Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013;774:1-20
   PubMed Web of Science ®Google Scholar
• Chow TF, Youssef YM, Lianidou E, et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010;43(1-2):150-8
   PubMed Web of Science ®Google Scholar
• Nagaraja AK, Creighton CJ, Yu Z, et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol (Baltimore, Md) 2010;24(2):447-63
   PubMed Web of Science ®Google Scholar
• Fornari F, Milazzo M, Chieco P, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010;70(12):5184-93
   PubMed Web of Science ®Google Scholar
• Kobori M, Iwashita K, Shinmoto H, Tsushida T. Phloretin-induced apoptosis in B16 melanoma 4A5 cells and HL60 human leukemia cells. Biosci Biotechnol Biochem 1999;63(4):719-25
   PubMed Web of Science ®Google Scholar
• Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010;70(8):848-55
   PubMed Web of Science ®Google Scholar
• Jiang X, Xin H, Ren Q, et al. Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials 2014;35(1):518-29
   PubMed Web of Science ®Google Scholar
• Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 2010;86(3):410-20
   PubMed Web of Science ®Google Scholar
• Milane L, Duan Z, Amiji M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One 2011;6(9):e24075
   PubMed Web of Science ®Google Scholar
• Milane L, Duan ZF, Amiji M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. 2011;7(4):435-44
   Google Scholar
• Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001;173(1):83-91
   PubMed Web of Science ®Google Scholar
• Clem B, Telang S, Clem A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 2008;7(1):110-20
   PubMed Web of Science ®Google Scholar
• Vuyyuri SB, Rinkinen J, Worden E, et al. Ascorbic acid and a cytostatic inhibitor of glycolysis synergistically induce apoptosis in non-small cell lung cancer cells. PLoS One 2013;8(6):e67081
   PubMedGoogle Scholar
• Porporato PE, Dhup S, Dadhich RK, et al. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011;2:49
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Christofk HR, Schuman E, et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 2010;79(8):1118-24
   PubMed Web of Science ®Google Scholar
• Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 2012;209(2):217-24
   PubMed Web of Science ®Google Scholar
• Guo W, Zhang Y, Chen T, et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 2011;137(1):65-72
   PubMed Web of Science ®Google Scholar
• Shi HS, Li D, Zhang J, et al. Silencing of PKM-2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 2010;101(6):1447-53
   PubMed Web of Science ®Google Scholar
• Kung C, Hixon J, Choe S, et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol 2012;19(9):1187-98
   PubMed Web of Science ®Google Scholar
• Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006;9(6):425-34
   PubMed Web of Science ®Google Scholar
• Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010;107(5):2037-42
   PubMed Web of Science ®Google Scholar
• Granchi C, Roy S, Giacomelli C, et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem 2011;54(6):1599-612
   PubMed Web of Science ®Google Scholar
• McCarty MF, Whitaker J. Manipulating tumor acidification as a cancer treatment strategy. Alternative Med Rev 2010;15(3):264-72
   PubMed Web of Science ®Google Scholar
• Supino R, Petrangolini G, Pratesi G, et al. Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies. J Pharmacol Exp Ther 2008;324(1):15-22
   PubMed Web of Science ®Google Scholar
• Leeper DB, Engin K, Thistlethwaite A, et al. Human tumor extracellular pH as a function of blood glucose concentration. Int J Radiat Oncol Biol Phy 1994;28(4):935-43
   PubMed Web of Science ®Google Scholar
• Burd R, Wachsberger PR, Biaglow JE, et al. Absence of Crabtree effect in human melanoma cells adapted to growth at low pH: reversal by respiratory inhibitors. Cancer Res 2001;61(14):5630-5
   PubMed Web of Science ®Google Scholar
• Han YH, Kim SW, Kim SH, et al. 2,4-dinitrophenol induces G1 phase arrest and apoptosis in human pulmonary adenocarcinoma Calu-6 cells. Toxicol Vitro 2008;22(3):659-70
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009;16(6):510-20
   PubMed Web of Science ®Google Scholar
• Karmali PP, Kotamraju VR, Kastantin M, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. 2009;5(1):73-82
   Google Scholar
• Dell'Antone P. Inactivation of H+-vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent. Life Sci 2006;79(21):2049-55
   PubMed Web of Science ®Google Scholar
• Bader AG, Brown D, Winkler M. The promise of MicroRNA replacement therapy. Cancer Res 2010;70(18):7027-30
   PubMed Web of Science ®Google Scholar
• Ganesh S, Iyer AK, Weiler J, et al. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic Acids 2013;2(1):e110
   Google Scholar
• Cortes-Cros M, Hemmerlin C, Ferretti S, et al. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci USA 2013;110(2):489-94
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Lunt SY, Dayton TL, et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol 2011;76:325-34
   PubMedGoogle Scholar
• Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4(6):437-47
   PubMed Web of Science ®Google Scholar